Genodix Products for Neurological Disorders

Genodix first entry into the market of treatments for neurological disorders is Entarol. As a dopaminergic analog, Entarol has been shown in clinical trials to both reduce the symptoms of Parkinson's disease as well as slow its progress. Entarol has been helping those who suffer from the devastating effects of Parkinson's disease for over a year without any reported major side effects. Wider use of Entarol is expected as physicans become more familiar with its benefits.






Inalis represents Genodix's latest entry into the neurological field, and its first in the treatment of Alzheimer's disease. The remarkable insights of Genodix's cheif scientist Carl Pauling led to the targeting of a specific neuronal receptor in the brain (also discovered by Pauling). While it's unknown what the precise function of this receptor is, targeting it with small molecules such as Inalis have shown significant improvments in the cognitive and memory abilities of patients. Inalis is currently in phase three clinical trials with the Food and Drug Administration, and should be available through a physician in the near future.